These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
222 related articles for article (PubMed ID: 25783982)
1. Reinvention of chemotherapy: drug conjugates and nanoparticles. Nguyen-Ngoc T; Raymond E Curr Opin Oncol; 2015 May; 27(3):232-42. PubMed ID: 25783982 [TBL] [Abstract][Full Text] [Related]
2. Protein nanoparticles as drug carriers in clinical medicine. Hawkins MJ; Soon-Shiong P; Desai N Adv Drug Deliv Rev; 2008 May; 60(8):876-85. PubMed ID: 18423779 [TBL] [Abstract][Full Text] [Related]
3. Direct comparison of two albumin-based paclitaxel-loaded nanoparticle formulations: is the crosslinked version more advantageous? Li C; Li Y; Gao Y; Wei N; Zhao X; Wang C; Li Y; Xiu X; Cui J Int J Pharm; 2014 Jul; 468(1-2):15-25. PubMed ID: 24709221 [TBL] [Abstract][Full Text] [Related]
4. Enhanced drug-loading and therapeutic efficacy of hydrotropic oligomer-conjugated glycol chitosan nanoparticles for tumor-targeted paclitaxel delivery. Koo H; Min KH; Lee SC; Park JH; Park K; Jeong SY; Choi K; Kwon IC; Kim K J Control Release; 2013 Dec; 172(3):823-31. PubMed ID: 24035978 [TBL] [Abstract][Full Text] [Related]
5. Comparative evaluation of novel biodegradable nanoparticles for the drug targeting to breast cancer cells. Mattu C; Pabari RM; Boffito M; Sartori S; Ciardelli G; Ramtoola Z Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):463-72. PubMed ID: 23916461 [TBL] [Abstract][Full Text] [Related]
6. Enhancing intracellular taxane delivery: current role and perspectives of nanoparticle albumin-bound paclitaxel in the treatment of advanced breast cancer. Guarneri V; Dieci MV; Conte P Expert Opin Pharmacother; 2012 Feb; 13(3):395-406. PubMed ID: 22263900 [TBL] [Abstract][Full Text] [Related]
7. Benefit of anti-HER2-coated paclitaxel-loaded immuno-nanoparticles in the treatment of disseminated ovarian cancer: Therapeutic efficacy and biodistribution in mice. Cirstoiu-Hapca A; Buchegger F; Lange N; Bossy L; Gurny R; Delie F J Control Release; 2010 Jun; 144(3):324-31. PubMed ID: 20219607 [TBL] [Abstract][Full Text] [Related]
8. Nanoformulation of paclitaxel to enhance cancer therapy. Gu Q; Xing JZ; Huang M; Zhang X; Chen J J Biomater Appl; 2013 Aug; 28(2):298-307. PubMed ID: 22561979 [TBL] [Abstract][Full Text] [Related]
9. Polymer nanoparticles--a novel strategy for administration of Paclitaxel in cancer chemotherapy. Deepa G; Ashwanikumar N; Pillai JJ; Kumar GS Curr Med Chem; 2012; 19(36):6207-13. PubMed ID: 22834822 [TBL] [Abstract][Full Text] [Related]
10. A review of the ligands and related targeting strategies for active targeting of paclitaxel to tumours. Li J; Wang F; Sun D; Wang R J Drug Target; 2016 Aug; 24(7):590-602. PubMed ID: 26878228 [TBL] [Abstract][Full Text] [Related]
11. Nanopaclitaxel therapy: an evidence based review on the battle for next-generation formulation challenges. Barkat MA; Beg S; Pottoo FH; Ahmad FJ Nanomedicine (Lond); 2019 May; 14(10):1323-1341. PubMed ID: 31124758 [TBL] [Abstract][Full Text] [Related]
12. Targeted delivery for breast cancer therapy: the history of nanoparticle-albumin-bound paclitaxel. Petrelli F; Borgonovo K; Barni S Expert Opin Pharmacother; 2010 Jun; 11(8):1413-32. PubMed ID: 20446855 [TBL] [Abstract][Full Text] [Related]
13. Paclitaxel-loaded Pluronic nanoparticles formed by a temperature-induced phase transition for cancer therapy. Oh KS; Song JY; Cho SH; Lee BS; Kim SY; Kim K; Jeon H; Kwon IC; Yuk SH J Control Release; 2010 Dec; 148(3):344-50. PubMed ID: 20797418 [TBL] [Abstract][Full Text] [Related]
14. A new approach to second-line therapy for urothelial cancer? Sonpavde G; Galsky MD; Bellmunt J Lancet Oncol; 2013 Jul; 14(8):682-4. PubMed ID: 23706984 [No Abstract] [Full Text] [Related]
15. Efficient delivery of therapeutic agents by using targeted albumin nanoparticles. Kouchakzadeh H; Safavi MS; Shojaosadati SA Adv Protein Chem Struct Biol; 2015; 98():121-43. PubMed ID: 25819278 [TBL] [Abstract][Full Text] [Related]
16. Tumor suppression via paclitaxel-loaded drug carriers that target inflammation marker upregulated in tumor vasculature and macrophages. Park S; Kang S; Chen X; Kim EJ; Kim J; Kim N; Kim J; Jin MM Biomaterials; 2013 Jan; 34(2):598-605. PubMed ID: 23099063 [TBL] [Abstract][Full Text] [Related]
17. Preparation and physicochemical characterization of a novel paclitaxel-loaded amphiphilic aminocalixarene nanoparticle platform for anticancer chemotherapy. Weeden C; Hartlieb KJ; Lim LY J Pharm Pharmacol; 2012 Oct; 64(10):1403-11. PubMed ID: 22943171 [TBL] [Abstract][Full Text] [Related]
18. Free paclitaxel loaded PEGylated-paclitaxel nanoparticles: preparation and comparison with other paclitaxel systems in vitro and in vivo. Lu J; Chuan X; Zhang H; Dai W; Wang X; Wang X; Zhang Q Int J Pharm; 2014 Aug; 471(1-2):525-35. PubMed ID: 24858391 [TBL] [Abstract][Full Text] [Related]